Phase 2 trial data presented at ARVO 2025 shows Innovent's efdamrofusp alfa (IBI302) achieved comparable visual acuity improvements to aflibercept with over 80% of patients maintaining benefits on a 12-week dosing schedule.
A recent clinical trial achieved its primary visual acuity endpoints in both the US and EU/UK, demonstrating statistically significant near vision improvements over 8 hours.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.